Giperplasticheskie protsessy endometriya: voprosy patogeneticheskoy terapii

The paper discusses pathogenetically based treatment choices and dosing regimens for patients with endometrial hyperplasia, aiming to reduce the need for radical surgical interventions and lower endometrial cancer incidence. It reports that prolonged use of combined oral contraceptives containing 30 μg ethinyl estradiol and 75 μg gestodene is presented as an effective approach for postoperative relapse prevention in endometrial hyperplasia and for prevention of endometrial (body of uterus) cancer. The key limitation is that the provided text is an abstract-level discussion without detailed study design, sample characteristics, outcomes, or quantitative results. This paper is centrally about endometriosis — it focuses on endometrial hyperplasia and therapy rather than endometriosis, but it is included in the corpus due to keyword alignment with endometrial pathology.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works